CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Mylan Pharmaceuticals Inc. et al. vs. Regeneron Pharmaceuticals, Inc.

Explore the PTAB proceeding IPR2021-00880 filed by Mylan Pharmaceuticals Inc. et al. on 2021-05-05. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2021-00880

Filing Date

2021-05-05

Accorded Filing Date

2021-05-05

Institution Decision Date

2021-11-10

Last Modified Date

2024-07-19

Proceeding Type

IPR

Termination Date

2022-11-09

Trial Status

Final Written Decision

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 14972560
Respondent Patent Number 9669069
Legal Expiration Date
2035-12-17 Active (9.1 yrs remaining)
Injunction Viability (35 U.S.C. ยง 283) Active Threat
Respondent Inventor George D. YANCOPOULOS
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

3 Total

Proceeding Status

Final Written Decision

Board Decisions & Rulings (3)

Dismissed 2024-07-19
Other: Fed Circuit mandate
35 U.S.C. Trial Decision
Final Written Decision 2022-11-09
Final Written Decision: original
37 CFR 42.73, 35 USC 312, 35 USC 314, 35 USC 318
Institution Granted 2021-11-10
Institution Decision: Grant
35 USC 325, 35 USC 314

Address and Attorney/Agent Information

23 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name A&P - Regeneron (Prosecution)
Customer Number 191459
Address 601 Massachusetts Ave., NW, Washington, DC, 20001-3743, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
41408 David Marsh +1 202-942-5068
48001 Thomas Triolo +1 914-847-1612
48921 Stephen Gaudet +1 914-847-7376
50370 Neil Miyamoto +1 914-847-7175
50437 Frank Cottingham +1 914-593-1116
58583 Brian Cocca +1 914-847-1421
58714 Ilona Gont +1 914-847-1304
59668 Brandon Schurter +1 914-847-7000

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 18 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials 10 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (18): ๐Ÿ‡บ๐Ÿ‡ธ US ๐ŸŒ PCT
Parallel Proceedings Across Jurisdictions (10 found):
PTAB: 10
USPTO PTAB Trial 2025-07-14
IPR2025-01269

Fresenius Kabi SwissBiosim, GmbH et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10828345)
Status: Institution Denied
USPTO PTAB Trial 2023-12-18
IPR2024-00298

Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-12-14
IPR2024-00260

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-11-20
IPR2024-00201

Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-04-27
IPR2023-00884

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11253572)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-03-26
IPR2023-00739

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2023-02-10
IPR2023-00566

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Final Written Decision
USPTO PTAB Trial 2023-02-10
IPR2023-00532

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10130681)
Status: Final Written Decision
USPTO PTAB Trial 2023-02-10
IPR2023-00533

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10888601)
Status: Final Written Decision
USPTO PTAB Trial 2023-01-06
IPR2023-00442

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (10130681)
Status: Final Written Decision
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Proceeding Documents

200
92

Other: Fed Circuit mandate OTHER

2024-07-19 FILING PARTY: BOARD
91

Patent Owner's Notice of Appeal NOTICE

2023-01-10 FILING PARTY: PATENT OWNER
90

Petitioner's Amended Mandatory Notices NOTICE

2022-12-29 FILING PARTY: PETITIONER
3002

Ex. 3002 Exhibit

2022-11-09 FILING PARTY: BOARD
89

Final Written Decision: original FINAL

2022-11-09 FILING PARTY: BOARD

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc